Telomir Pharmaceuticals (NASDAQ: TELO) announced new research findings from The Ohio State University College of Veterinary Medicine showing that Telomir-Zn produced growth inhibition across human and canine osteosarcoma cell-line models at similar low drug concentrations. The study, led by Shay Bracha, DVM, MS, DACVIM (Oncology), evaluated Telomir-Zn in one human and two canine osteosarcoma models. These results support further translational investigation and a potential development pathway using naturally occurring canine osteosarcoma.
The significance of this research lies in its cross-species validation. Osteosarcoma is a rare but aggressive bone cancer that affects both humans and dogs, with limited treatment options. The fact that Telomir-Zn inhibited growth in both human and canine cell lines at comparable low concentrations suggests a shared mechanism that could be exploited therapeutically. This opens the door to a streamlined development strategy where canine osteosarcoma, which occurs naturally in dogs, can serve as a translational model for human disease.
Telomir is in discussions with The Ohio State University College of Veterinary Medicine and is assessing next steps for a potential in vivo efficacy study in canine osteosarcoma. Such a study could support both veterinary development and translational advancement toward human osteosarcoma. If successful, this approach could accelerate the timeline for bringing a new treatment to both veterinary and human patients, leveraging the similarities in disease biology.
While the osteosarcoma findings are promising, the company said its immediate focus remains its triple-negative breast cancer program. Telomir-Zn is advancing toward site initiation and Phase 1/2 patient enrollment under an active FDA-cleared Investigational New Drug (IND) application for advanced or metastatic triple-negative breast cancer (TNBC). TNBC is an aggressive subtype of breast cancer with limited targeted therapies, and the company's lead program aims to address this unmet need by modulating intracellular metal homeostasis and epigenetic regulation.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company's lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation. The FDA's IND clearance for the Phase 1/2 trial in TNBC marks a critical milestone for the company.
For investors, the osteosarcoma data represent an additional potential value driver beyond the lead breast cancer program. The ability to pursue a veterinary indication first could provide early clinical proof-of-concept and revenue opportunities while the human trials progress. However, the company has not yet committed to an in vivo study, and further preclinical work is needed. The market will likely watch for updates on both the TNBC trial initiation and any formal plans for the canine osteosarcoma study.
To view the full press release, visit https://nnw.fm/laeGH. For more information about Telomir Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TELO. NetworkNewsWire is a specialized communications platform focused on financial news and content distribution, and is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. For more information, visit https://www.NetworkNewsWire.com.
